Literature DB >> 10481770

[Combined treatment of localized prostate cancer with HDR-Iridium 192 remote brachytherapy and external beam irradiation].

D Andreopoulos1, M Piatkowiak, B Krenkel, U M Schleicher, J M Wolff.   

Abstract

BACKGROUND: The localized prostate cancer can be treated curatively by radiation therapy. The combined treatment of external beam irradiation and HDR-Iridium 192 remote brachytherapy allows higher radiation doses within the tumor without increasing radiation sequelae. PATIENTS AND METHODS: Patients of our clinic have been treated with this combined procedure since 1991. Between 1991 and 1994 15 patients received 2 x 9 Gy of high-dose-rate brachytherapy, followed by 36 Gy external beam irradiation (group A). Because of the frequent local failures in group A, the reference dose of external beam irradiation was increased to 50.4 Gy after brachytherapy between 1994 and 1996.
RESULTS: Seven of 15 patients (47%) in group A developed a local recurrence after a median of 17 (13 to 30) months. In group B (20 patients) local failure occurred in 3 patients (15%) after 11, 16 and 32 months.
CONCLUSION: The combined radiation therapy of localized prostate cancer cannot substitute radical prostatectomy completely, but it is a promising alternative in the curative treatment in selected patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10481770     DOI: 10.1007/s000660050026

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  2 in total

1.  Advantage of robotic needle placement on a prostate model in HDR brachytherapy.

Authors:  Gerd Strassmann; Peter Olbert; Axel Hegele; Detlev Richter; Emmanouil Fokas; Nina Timmesfeld; Rainer Hofmann; Rita Engenhart-Cabillic
Journal:  Strahlenther Onkol       Date:  2011-05-17       Impact factor: 3.621

Review 2.  [Curative radiotherapy of localized prostate cancer. Treatment methods and results].

Authors:  R Schwarz
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.